Palvella Therapeutics Inc (PVLA) Actualités

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations

Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™...

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

        Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare...